Development of novel quality control material based on CRISPR/Cas9 editing and xenografts for MLH1 protein deficiency testing

Development of novel quality control material based on CRISPR/Cas9 editing and xenografts for MLH1 protein deficiency testing

Background: Mismatch repair deficiency (dMMR) status induced by MLH1 protein deficiency plays a pivotal role in therapeutic decision-making for cancer patients. Appropriate quality control (QC) materials are necessary for monitoring the accuracy of MLH1 protein deficiency assays used in clinical lab...

Full description

Bibliographic Details
Main Authors: Chen, Y. (Author), Han, D. (Author), Han, Y. (Author), Li, J. (Author), Li, R. (Author), Tan, P. (Author), Wang, M. (Author), Zhang, J. (Author), Zhang, R. (Author)
Format: Article
Language:English
Published: John Wiley and Sons Inc 2021
Subjects:
animal
Animals
Article
Base Sequence
cancer cell line
cell clone
cell culture
cell line
Cell Line
cell selection
CRISPR Cas system
CRISPR/Cas9
CRISPR-Cas Systems
CRISPR-CAS9 system
drug screening
eosin
formaldehyde
formalin fixed paraffin embedded
gene editing
Gene Editing
gene mutation
genetics
GM12878Cas9 10 cell line
GM12878Cas9 6 cell line
hematoxylin
high throughput sequencing
human
human cell
human tissue
Humans
immunohistochemistry
Mice, Inbred NOD
Mice, SCID
MLH1
MLH1 gene
MLH1 protein deficiency
mutation
Mutation
MutL protein homolog 1
MutL Protein Homolog 1
next-generation sequencing
nonobese diabetic mouse
nucleotide sequence
paraffin embedding
protein analysis
protein deficiency
protein expression
quality control
Quality Control
quality control material
Sanger sequencing
SCID mouse
stop codon
tissue fixation
tumor xenograft
Western blotting
Xenograft Model Antitumor Assays
Online Access:View Fulltext in Publisher

Internet

View Fulltext in Publisher

Similar Items